Headlines about CryoLife (NYSE:CRY) have trended somewhat positive on Thursday, according to Accern. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. CryoLife earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned news headlines about the medical equipment provider an impact score of 46.5530340417504 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the headlines that may have effected Accern’s rankings:

A number of brokerages have weighed in on CRY. Canaccord Genuity reaffirmed a “buy” rating and set a $25.00 target price on shares of CryoLife in a research note on Monday. Lake Street Capital raised their target price on shares of CryoLife to $26.00 and gave the company a “buy” rating in a research note on Wednesday. BidaskClub downgraded shares of CryoLife from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Finally, Zacks Investment Research raised shares of CryoLife from a “sell” rating to a “hold” rating in a research note on Monday, August 14th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $23.63.

Shares of CryoLife (CRY) opened at 20.00 on Thursday. The company’s 50 day moving average is $21.84 and its 200 day moving average is $19.17. The company has a market cap of $668.92 million, a P/E ratio of 60.61 and a beta of 0.92. CryoLife has a 12 month low of $14.02 and a 12 month high of $24.00.

CryoLife (NYSE:CRY) last posted its quarterly earnings data on Monday, July 24th. The medical equipment provider reported $0.12 EPS for the quarter, topping the consensus estimate of $0.10 by $0.02. The firm had revenue of $47.80 million during the quarter, compared to analyst estimates of $47.02 million. CryoLife had a net margin of 6.16% and a return on equity of 7.41%. CryoLife’s revenue was up 1.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.13 EPS. On average, equities research analysts predict that CryoLife will post $0.43 EPS for the current fiscal year.

In related news, Director James Benson sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $22.80, for a total transaction of $45,600.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO James P. Mackin sold 125,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $22.01, for a total transaction of $2,751,250.00. Following the transaction, the chief executive officer now owns 398,399 shares of the company’s stock, valued at approximately $8,768,761.99. The disclosure for this sale can be found here. In the last quarter, insiders have sold 171,050 shares of company stock valued at $3,769,825. 6.00% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY WARNING: “CryoLife (CRY) Given Daily Media Sentiment Score of 0.11” was published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/10/12/cryolife-cry-given-daily-media-sentiment-score-of-0-11.html.

About CryoLife

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Insider Buying and Selling by Quarter for CryoLife (NYSE:CRY)

Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.